Chikungunya spreads in southern China
The chikungunya virus was first identified in people sickened during an outbreak in Tanzania in 1952. Its name is derived from a word in the Makonde language, which means 'that which bends up,' due to the severe pain it can cause.
Chikungunya is transmitted by infected mosquitoes and mostly causes mild symptoms. The majority of people who get chikungunya recover without needing medical attention after one to two weeks.
Advertisement
What are the symptoms of chikungunya?
Chikungunya typically produces symptoms including fever, muscle pain, nausea, fatigue, and a rash.
But in rare cases, it can cause debilitating joint pain that persists for months or even years. Patients who get severely ill often require hospitalization because of the risk of organ damage.
The World Health Organization says severe cases and deaths are rare and mostly occur in babies or elderly people with underlying health conditions.
Is there a treatment or vaccine?
There is no specific treatment for chikungunya, but health workers can treat the symptoms by giving medicines to lower fevers or ease muscle pain.
Two vaccines have been approved in several regions, including Britain, Brazil, Canada, and Europe. Those are mostly targeted at travelers and are not widely available in the countries most affected by chikungunya.
Where does chikungunya normally occur?
Chikungunya causes regular outbreaks in Africa, Asia, and the Americas, with occasional small epidemics in Europe.
Advertisement
As of July, there have been about 240,000 cases of chikungunya, including 90 deaths in 16 countries, according to the European Centres for Disease Prevention and Control. The countries that reported the highest number of infections were Brazil, Bolivia, Argentina, and Peru.
What's happening in China?
With thousands of confirmed cases, this appears to be the biggest chikungunya outbreak ever documented in China, according to César López-Camacho of the University of Oxford.
'What makes this event notable is that chikungunya has never been established in mainland China before,' he said in a statement. 'This suggests that most of the population had no preexisting immunity, making it easier for the virus to spread quickly.'
In response to the outbreak in Foshan, near Hong Kong, Chinese authorities have begun taking measures like distributing mosquito nets, having workers spray residential areas, streets, and construction sites with insecticide.
People who do not empty bottles, flower pots, or other outdoor receptacles, where water might accumulate and allow mosquitoes to breed, can be subject to fines of up to 10,000 yuan ($1,400) and have their electricity cut off.
Unusually heavy rains and high temperatures this year have worsened the crisis in China.
Are we seeing more chikungunya outbreaks?
Yes.
The number of outbreaks has increased since 2000, just as there have been more outbreaks of other mosquito-transmitted diseases like dengue and Zika, according to Robert Jones, an assistant professor at the London School of Hygiene and Tropical Medicine.
Jones said in a statement that in 2013, chikungunya was first seen in the island of St. Martin and that over the next three years, cases were confirmed in almost 50 countries in the Caribbean and the Americas, with more than one million suspected cases.
Advertisement
Jones said the risks of chikungunya epidemics have risen due to climate change and urban expansion, warning that the current outbreak could spread to other parts of southern China with humid climates and dense cities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Scientists make incredible plant discovery that could help solve major issue in food system: 'It's the signal that initiates healing'
Scientists make incredible plant discovery that could help solve major issue in food system: 'It's the signal that initiates healing' Scientists at the University of Helsinki have found that plants use gas movement to heal their protective outer layers. When a plant's outer cork layer gets damaged, gases shift. Ethylene escapes while oxygen flows in through the wound. This simple gas exchange tells the plant to start repairs. The protective cork layer, called the periderm, normally blocks gases from moving in or out, which creates conditions where ethylene (a plant hormone) builds up inside while oxygen levels drop due to the plant's natural growth processes. When damage occurs, this balance gets disrupted. "Gas diffusion through a wound isn't just a consequence of injury — it's the signal that initiates healing," explained Dr. Hiroyuki Iida, the lead scientist on the project. The team first noticed ethylene's role in healing, then worked with University of Oxford Professor Francesco Licausi to confirm oxygen's importance, too. Once repairs finish and the barrier seals back up, gases again accumulate inside the plant, which signals that healing can stop and normal growth can resume. This elegant detection system works without complex sensors, using basic physics to monitor barrier integrity. This discovery holds promise for the future of food waste and crop resilience. Potatoes, carrots, fruits, and other produce with damaged outer layers tend to lose water and become more susceptible to disease, ultimately leading to spoilage. By studying and improving this natural repair system, farmers might grow plants that handle dry conditions better, while picked produce could stay fresh for longer in stores. With warming temperatures and growing populations putting pressure on global food systems, this finding creates promising paths for more sustainable farming. Improving how plants heal could help feed more people while cutting waste throughout the food supply chain. Researchers are now exploring practical uses that could reach farms and food storage facilities within the next few years. What is the biggest reason you don't grow food at home? Not enough time Not enough space It seems too hard I have a garden already Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
China's clinical trial ecosystem takes centre stage in Suzhou this September
China's rapid emergence as a global clinical trials powerhouse will be in sharp focus this September as leading voices from the biopharma and healthcare sectors convene in Suzhou for the launch of Outsourcing in Clinical Trials China and Clinical Trial Supply China. Held over two days on 3-4 September 2025, the dual event brings together senior executives, regulators, and innovators across R&D, clinical operations, outsourcing, and supply chain to examine the evolving landscape of clinical development in China - arguably the world's most dynamic biopharma market. Strategic inflection point China's clinical trials sector has undergone significant structural transformation over the past five years, driven by a combination of regulatory shifts, capital inflows into biotech, and a shift toward more decentralised, patient-centric trial models. According to GlobalData analysis, China now surpasses the US for annual number of clinical trials. Yet as the ecosystem expands, so too does its complexity - particularly in relation to cross-border compliance, data protection, and clinical logistics. This new industry event marks a pivotal moment, featuring an opening keynote panel on 'The Evolving Clinical Trial Landscape in China: Challenges & Opportunities,' alongside in-depth discussions on artificial intelligence in drug discovery, clinical supply chain management, and geopolitical risk. Sessions will span core operational challenges - including site selection, enhancing collaboration in outsourcing, comparator sourcing, cold chain logistics, and vendor management - as well as broader questions on global collaboration, clinical trial harmonisation, and China's biotech ambitions. The program includes a panel on 'The Rise of Chinese Biotech: A Competitive Challenge for US Companies and Investors,' reflecting growing interest in China's ability to scale R&D innovation, supported by state policy and venture capital. While China continues to make strides in drug discovery and innovation, integration into the global clinical development ecosystem remains uneven. Concerns around IP protection, regulatory uncertainty, and data localisation persist, particularly for international sponsors managing multi-country trials. Speakers from IDA Ireland, Singapore's Agency for Science, Technology and Research, and the US Maryland China Center will participate in a cross-border panel addressing the impact of China's biotech boom on global trials. On 4 September, delegates will have the opportunity to participate in a curated site visit to Biobay, the national biomedical innovation zone located in Suzhou Industrial Park. The tour includes direct engagement with local biotech executives and exposure to platform technologies shaping the next wave of drug development. Confirmed speakers include: Li Zeng, CEO, Jing Medicine Summer Xia, CEO, Trial-Data Medicine Vincent Zang, Senior Director, Clinical Trial Operation, Innovent Bio Angela Yu, Head of Outsourcing, East China Pharm Shen Xiao, CMO, Alebund Siwei Li, Director, Drug Metabolism and Pharmacokinetics, Degron Therapeutics Xiaoyu Deng, Founder, MDCE Medical Megan Qin, Head of Medical Device Clinical Excellence Working Group, CMAC Xiaoyu Deng, Founder, MDCE Medical Claire Qin, Chief Strategy Officer, Intelligen AI Min Geng, Head of Supply Chain, Shanghai Pharma Fiona Barry, Editor in Chief & Director, Globaldata Healthcare Shelly Xie，Associate Director, Clinical & QC Management,Eli Lilly Jinna Qin, President, China Association for Vaccines Daniel Gao, President, ISPE Supply Chain Committee Xiaomei Wang, VP of Clinical Trial Operation, Key Therapharma Yugang Ju, Head of Clinical Operation, Insilico Medicine Quancheng Chen, Agency for Science, Technology and Research, Singapore Chester Xiao, Head of Life Science Industry, IDA Ireland Vikki Wang, Head of China Center, U.S. Maryland China Center View the full list of speakers and the complete conference agenda here. Don't miss this exclusive opportunity to connect with industry leaders, gain actionable insights, and stay ahead in the rapidly evolving clinical trials landscape in China. Join the Outsourcing in Clinical Trials China & Clinical Trial Supply China, happening 3-4 September at the Renaissance Suzhou Hotel. Register here: "China's clinical trial ecosystem takes centre stage in Suzhou this September" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
4 hours ago
- Epoch Times
Don't Let Communist China Poison Our Path to a Healthier America
Communist China isn't just trying to compete with the United States in pharmaceuticals—it's trying to overtake us. Backed by massive state investment and regulatory shortcuts, China has quickly emerged as a global powerhouse in drug development. In 2024 alone, China conducted more clinical trials than the United States and is now developing almost as many new drugs as America is. While U.S. innovators are bogged down by bureaucratic red tape, Chinese companies are racing ahead, often with far less oversight. China's rise isn't just about innovation—it's about infiltration. Increasingly, unapproved and unregulated Chinese-made compounds —including weight-loss drugs—make their way into the United States through online compounding pharmacies, social media sellers, and sketchy e-commerce platforms. Many of these products evade scrutiny by the U.S. Food and Drug Administration; yet they're being consumed by millions of Americans who assume what they're taking has been properly vetted. This is more than a public health risk—it's a national security threat. The Chinese regime is exploiting the United States' regulatory gaps and consumer vulnerabilities, flooding the market with untested therapies while positioning itself as the world's next pharmaceutical superpower. Meanwhile, U.S. manufacturers face stricter standards and longer approval timelines, creating an uneven playing field that punishes American compliance and rewards Chinese circumvention. Take knock-off weight-loss treatments. More than 9 out of 10 Americans worry about what's in these drugs and where they come from. Indeed, such compounded medicines aren't coming from your trusted neighborhood pharmacy. They're being manufactured with ingredients often sourced from China, with little to no transparency about what's actually in them. No FDA approval. No clinical trials. Just chemical cocktails dressed up to look like legitimate treatments. The FDA has already issued strong public warnings about the risks of these unapproved GLP-1 drugs being used for weight loss. In fact, the agency has gone out of its way to warn doctors, patients, and compounders that these products are neither tested nor safe. But rather than heed those warnings, some of these compounders are thumbing their nose at federal regulators, ignoring the law, and continuing to crank out untested drugs. Fortunately, Congress is paying attention. Last month, a group of 80 lawmakers sent a letter to the Trump administration demanding a crackdown on these foreign-made, non-FDA-approved knock-off drugs. They rightly warned that this shadow market not only puts Americans at risk—it threatens to destabilize our entire pharmaceutical system. This isn't just about health. It's about sovereignty and security. While American companies play by the rules—undergo rigorous testing, FDA approval, and years of research and development—Chinese labs and compounders cut corners, flood our market, and profit off Americans trying to live healthy lives. Allowing compounders to churn out copycat GLP-1s creates a 'Wild West' in our supply chain, outsourcing critical medicines and bolstering a Chinese pharmaceutical industry that aims for global dominance. That undercuts U.S. manufacturing jobs and cedes strategic advantage to a geopolitical rival. The United States can't afford to sleepwalk into pharmaceutical dependence. When unregulated drugs from overseas flood our market and compounders openly defy FDA warnings, it sends a dangerous message: that we're willing to outsource public health to geopolitical rivals. China understands the stakes—that's why it's investing billions to become the world's medicine cabinet. Let's recognize China's pharmaceutical surge for what it is: a deliberate strategy to dominate the world's medicine supply. If we allow rogue compounders to undercut FDA standards and flood the market with unvetted weight-loss therapies, we're not just enabling a regulatory loophole—we're accelerating a dangerous shift in global pharmaceutical power. America must decide: do we want to hand our medicine supply over to a geopolitical rival that plays by a different set of rules? The more we tolerate this gray market, the more we erode the integrity of our pharmaceutical system and outsource our health security to a strategic competitor. We must make it absolutely clear that the United States is not open for business to unapproved drugs, whether for weight-loss or any other condition, especially ones built on foreign shortcuts and bad faith.
